Evidence map›Paper›PMID 32076823›Full record

ArticleJournal of cancer research and clinical oncology2020

Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry.

Sebastian Birndt, Thomas Schenk, Babett Heinevetter, Frank M Brunkhorst, Georg Maschmeyer, Frank Rothmann, Thomas Weber, Markus Müller, Jens Panse, Olaf Penack and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach usingCancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sebastian BirndtKlinik für Innere Medizin II, Abt. Hämatologie und Intern. Onkologie, Universitätsklinikum Jena, Jena, Germany.ORCID http://orcid.org/0000-0001-5430-899X
Thomas SchenkKlinik für Innere Medizin II, Abt. Hämatologie und Intern. Onkologie, Universitätsklinikum Jena, Jena, Germany.
Babett HeinevetterKlinik für Innere Medizin II, Abt. Hämatologie und Intern. Onkologie, Universitätsklinikum Jena, Jena, Germany.
Frank M BrunkhorstZentrum für Klinische Studien, Universitätsklinikum Jena, Jena, Germany.
Georg MaschmeyerKlinik für Hämatologie, Onkologie u. Palliativmedizin, Klinikum Ernst Von Bergmann, Potsdam, Germany.
Frank RothmannKlinik für Hämatologie, Onkologie u. Palliativmedizin, Klinikum Ernst Von Bergmann, Potsdam, Germany.
Thomas WeberKlinik für Hämatologie und Onkologie, Universitätsklinikum Halle (Saale), Halle, Germany.
Markus MüllerZentrum für Infektiologie und HIV, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany.
Jens PanseKlinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Uniklinik RWTH Aachen, Aachen, Germany.
Olaf PenackMedizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin, Berlin, Germany.
Roland SchroersHämatologie und Onkologie, Universitätsklinikum Knappschaftskrankenhaus, Bochum, Germany.
Jan BraessOnkologie und Hämatologie, Krankenhaus Barmherzige Brüder, Regensburg, Germany.
Norbert FrickhofenHämatologie, Onkologie und Palliativmedizin, HELIOS Dr. Horst Schmidt Kliniken, Wiesbaden, Germany.
Stephan EhlCentrum für Chronische Immundefizienz (CCI), Universitätsklinikum Freiburg, Freiburg, Germany.
Gritta JankaPädiatrische Hämatologie und Onkologie, Universitätsklinikum Eppendorf, Hamburg, Germany.
Kai LehmbergPädiatrische Hämatologie und Onkologie, Universitätsklinikum Eppendorf, Hamburg, Germany.
Mathias W PletzInstitut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Germany.
Andreas HochhausKlinik für Innere Medizin II, Abt. Hämatologie und Intern. Onkologie, Universitätsklinikum Jena, Jena, Germany.
Thomas ErnstKlinik für Innere Medizin II, Abt. Hämatologie und Intern. Onkologie, Universitätsklinikum Jena, Jena, Germany.
Paul La RoséeKlinik für Innere Medizin II, Hämatologie, Onkologie, Immunologie, Infektiologie und Palliativmedizin, Schwarzwald-Baar Klinikum, Klinikstr. 11, 78052, Villingen-Schwenningen, Germany. paul.larosee@sbk-vs.de.

Funding

Thüringer Aufbaubank Grant 2014 KN 0024
6 · The paper itself

Abstract

purposeHemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome emerging from a deregulated immune response due to various triggers. In adults, systematic data are sparse, which is why recommendations on diagnosis and management have been adopted from pediatric guidelines. A nationwide clinical registry with associated consulting service as collaborative initiative of HLH-specialized pediatricians and hematologists was initiated to better characterize HLH in adults.

methodsPatients with proven or suspected HLH were registered by 44 institutions. Both HLH-2004 diagnostic criteria and the HScore (www.saintantoine.aphp.fr/score/) were used to confirm HLH diagnosis. Data referring to underlying disease, treatment, outcome, clinical presentation and laboratory findings were recorded.

resultsThe study included 137 patients and provides the first systematic data on adult HLH in Germany. Median age was 50 years with a wide range (17-87 years), 87 patients (63.5%) were male. Most common triggering diseases were infections in 61 patients (44.5%) and malignancies in 48 patients (35%). Virtually all patients had elevated ferritin concentrations, and 74% had peak concentrations greater than 10,000 µg/l. At time of analysis, 67 of 131 patients (51%) had died. Patients with malignancy-associated HLH had the shortest median survival (160 days), however no statistically significant difference between subgroups was observed (p = 0.077). Platelets under 20*10

conclusionClose multidisciplinary case consultation and cooperation is mandatory when treating adult HLH patients. Early contact with reference centers is recommended, especially in relapsing or refractory disease.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleGermanyHumansLymphohistiocytosis, HemophagocyticMaleMiddle AgedPrognosisRegistriesYoung AdultCytokine stormHemophagocytic lymphohistiocytosisHLHInflammationSepsis

Identifiers

PMID32076823
PMCPMC7085479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.